Jeffrey G Supko, Ph.D.

Associate Investigator
Cancer Center, Mass General Research Institute
Associate Professor of Medicine
Harvard Medical School
Research Staff
Hematology-Oncology, Massachusetts General Hospital
PhD Ohio State College of Pharmacy 1988
anticancer agents; antineoplastic agents; antineoplastic combined chemotherapy protocols; camptothecin; chromatography high pressure liquid; isoquinolines; maximum tolerated dose; pharmacokinetics The Clinical Pharmacology Laboratory (CPL) provides clinical investigators in the Massachusetts General Hospital Cancer Center with the capabilities required to undertake the pharmacokinetic studies that are an important component of early phase clinical trials of investigational anticancer agents. An understanding of the pharmacokinetic behavior of an drug facilitates the rational determination of the dose, route and schedule of administration that maximizes the potential for therapeutic effectiveness while minimizing the likelihood of serious adverse effects. Acquiring pharmacokinetic data necessarily depends upon the ability to accurately and specifically measure the a drug or active metabolites in biological fluids. The development, validation and application of bioanalytical methods, especially those based upon high performance liquid chromatography with mass spectrometric detection (LC/MS), is a major activity of the laboratory. The CPL has been instrumental in characterizing the pharmacokinetic behavior of many structurally diverse chemotherapeutic agents. The two recently completed studies that are summarized below illustrate the important role of pharmacokinetic studies in the development and evaluation of new strategies for treating solid malignancies and brain tumors.
Supko Lab Publications

Gray / Jackson
80 Blossom Street
Boston, MA 02114